Valuation post CYB004 Phase 2 Data

I am heavily invested in Cybin so definitely looking for some critique as my Bias is huge.

If Phase 2 Data is good(I expect 50 percent remission after 2 doses or better), with 2 potential breakthrough therapies with chances to be best in class therapies and shorter acting with improved pharmacology, I can‘t imagine for Cybin to stay below a valuation of 1 Billion Dollars, even 5-10 billion would be an appropriate valuation if I compare it to other biotech companies. For example, Karuna after good but not impressive phase 2 data also saw a rise of the valuation into the billions.

Compass phase 3 data should obviously help the entire sector.

What‘s your prediction for the next weeks?